Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atacicept in optic neuritis as clinically isolated syndrome
2007-003925-26Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Jan 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in optic neuritis (ON) comparing Atacicept with Placebo (2 arms). Primary endpoint: Change in retinal nerve fiber layer thickness in the affected eye. Started Jan 2008; status: completed.
02
Drugs
atacicept
03
Conditions
optic neuritis (ON)
Beyond the preview
Go deeper on 2007-003925-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003925-26.